Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy ...Middle East

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific...

Hence then, the article about akeso announces first patient dosed in phase iii trial of ivonescimab as consolidation therapy for limited stage sclc after definitive radiotherapy was published today ( Monday 11/08/2025 - 06:02 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy )

Also on site :

• The ‘rules-based order’ has failed in its mission – helping the West do whatever it wants
• Armed police close Lewes Road
• Intrigue, Power Plays and Rivalries: Inside the Rise of Mojtaba Khamenei